.avif)
MSI/dMMR Test - Endometrial Cancer Biomarker
This MSI/dMMR test detects microsatellite instability or deficient DNA mismatch repair in tumors—markers of Lynch syndrome and MSI‑high cancers—so your care team can personalize treatment (including immunotherapy) and pursue family genetic assessment. By identifying risk early, it may prompt increased screening or preventive steps that help reduce the chance of advanced colorectal, endometrial and other Lynch‑associated cancers.
ER/PR Test - Endometrial Cancer Biomarker
The ER/PR test checks whether breast tumor cells express estrogen and progesterone receptors so clinicians can choose the most effective, hormone-targeted therapies. Knowing ER/PR status can help avoid ineffective treatments and may reduce the risk of cancer progression or recurrence.
POLE Mutation Test - Endometrial Cancer Biomarker
A POLE mutation test detects inherited or tumor changes in the POLE gene that raise risk for early-onset colorectal cancer, endometrial cancer and multiple polyps. Knowing your POLE status enables earlier surveillance, preventive steps and tailored treatment decisions that can help catch cancer sooner or reduce your risk.
PTEN Mutation Test - Endometrial Cancer Biomarker
This PTEN mutation test detects pathogenic changes in the PTEN gene to identify individuals at risk for PTEN hamartoma tumor syndrome. Results enable targeted surveillance and early intervention that can help prevent or detect early PTEN‑associated problems such as breast, thyroid, endometrial and colorectal cancers, benign hamartomas, and certain developmental issues.
P53 Gene Test - Endometrial Cancer Biomarker
This TP53 (p53) gene test identifies inherited mutations that markedly increase risk of multiple early-onset cancers. Knowing your status enables targeted surveillance and preventive steps to catch or reduce risk of cancers such as breast cancer, soft‑tissue and bone sarcomas, brain tumors, adrenocortical carcinoma, and certain leukemias.
ER/PR Test - Endometrial Cancer Biomarker
The ER/PR test checks whether breast tumor cells have estrogen and progesterone receptors to determine if hormone (endocrine) therapy is likely to work. Knowing receptor status helps avoid ineffective treatments and can reduce the risk of cancer progression and recurrence.
POLE Mutation Test - Endometrial Cancer Biomarker
This POLE mutation test checks for harmful changes in the POLE gene that are linked to polymerase proofreading–associated polyposis and an increased risk of colorectal and endometrial cancer. Knowing your POLE status enables earlier surveillance, targeted prevention, and informed treatment planning to lower the chance of advanced cancer.
PTEN Mutation Test - Endometrial Cancer Biomarker
This PTEN mutation test screens for harmful variants in the PTEN gene linked to PTEN hamartoma tumor syndrome (including Cowden syndrome) to clarify inherited cancer risk. Results can prompt personalized surveillance and preventive care to help detect or reduce risk of PTEN‑related conditions such as breast, thyroid, endometrial, renal and colorectal cancers and certain developmental issues.
P53 Gene Test - Endometrial Cancer Biomarker
This P53 (TP53) gene test detects pathogenic changes in the TP53 tumor‑suppressor gene to identify inherited cancer risk (Li‑Fraumeni syndrome) or tumor-specific mutations that inform surveillance and treatment. Early detection of TP53 alterations can help you and your clinician take preventive steps and intensify monitoring to reduce the chance of late-stage breast cancer, sarcomas, brain tumors, adrenocortical carcinoma, leukemia and other TP53‑associated cancers.
.svg)
